122 related articles for article (PubMed ID: 12028033)
1. FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance.
Rasmussen T; Hudlebusch HR; Knudsen LM; Johnsen HE
Br J Haematol; 2002 Jun; 117(3):626-8. PubMed ID: 12028033
[TBL] [Abstract][Full Text] [Related]
2. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
[TBL] [Abstract][Full Text] [Related]
3. A molecular study of the t(4;14) in multiple myeloma.
Sibley K; Fenton JA; Dring AM; Ashcroft AJ; Rawstron AC; Morgan GJ
Br J Haematol; 2002 Aug; 118(2):514-20. PubMed ID: 12139740
[TBL] [Abstract][Full Text] [Related]
4. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
[TBL] [Abstract][Full Text] [Related]
5. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
Keats JJ; Reiman T; Maxwell CA; Taylor BJ; Larratt LM; Mant MJ; Belch AR; Pilarski LM
Blood; 2003 Feb; 101(4):1520-9. PubMed ID: 12393535
[TBL] [Abstract][Full Text] [Related]
6. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
[TBL] [Abstract][Full Text] [Related]
7. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells.
Li Z; Zhu YX; Plowright EE; Bergsagel PL; Chesi M; Patterson B; Hawley TS; Hawley RG; Stewart AK
Blood; 2001 Apr; 97(8):2413-9. PubMed ID: 11290605
[TBL] [Abstract][Full Text] [Related]
8. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
Dring AM; Davies FE; Fenton JA; Roddam PL; Scott K; Gonzalez D; Rollinson S; Rawstron AC; Rees-Unwin KS; Li C; Munshi NC; Anderson KC; Morgan GJ
Clin Cancer Res; 2004 Sep; 10(17):5692-701. PubMed ID: 15355895
[TBL] [Abstract][Full Text] [Related]
9. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
Santra M; Zhan F; Tian E; Barlogie B; Shaughnessy J
Blood; 2003 Mar; 101(6):2374-6. PubMed ID: 12433679
[TBL] [Abstract][Full Text] [Related]
10. Identification of ID-1 as a potential target gene of MMSET in multiple myeloma.
Hudlebusch HR; Theilgaard-Mönch K; Lodahl M; Johnsen HE; Rasmussen T
Br J Haematol; 2005 Sep; 130(5):700-8. PubMed ID: 16115125
[TBL] [Abstract][Full Text] [Related]
11. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
[TBL] [Abstract][Full Text] [Related]
12. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.
Plowright EE; Li Z; Bergsagel PL; Chesi M; Barber DL; Branch DR; Hawley RG; Stewart AK
Blood; 2000 Feb; 95(3):992-8. PubMed ID: 10648414
[TBL] [Abstract][Full Text] [Related]
13. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.
Brito JL; Walker B; Jenner M; Dickens NJ; Brown NJ; Ross FM; Avramidou A; Irving JA; Gonzalez D; Davies FE; Morgan GJ
Haematologica; 2009 Jan; 94(1):78-86. PubMed ID: 19059936
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma.
Chang H; Stewart AK; Qi XY; Li ZH; Yi QL; Trudel S
Blood; 2005 Jul; 106(1):353-5. PubMed ID: 15761022
[TBL] [Abstract][Full Text] [Related]
15. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).
Intini D; Baldini L; Fabris S; Lombardi L; Ciceri G; Maiolo AT; Neri A
Br J Haematol; 2001 Aug; 114(2):362-4. PubMed ID: 11529856
[TBL] [Abstract][Full Text] [Related]
16. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.
Lauring J; Abukhdeir AM; Konishi H; Garay JP; Gustin JP; Wang Q; Arceci RJ; Matsui W; Park BH
Blood; 2008 Jan; 111(2):856-64. PubMed ID: 17942756
[TBL] [Abstract][Full Text] [Related]
17. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
[TBL] [Abstract][Full Text] [Related]
18. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
Paterson JL; Li Z; Wen XY; Masih-Khan E; Chang H; Pollett JB; Trudel S; Stewart AK
Br J Haematol; 2004 Mar; 124(5):595-603. PubMed ID: 14871245
[TBL] [Abstract][Full Text] [Related]
19. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
[TBL] [Abstract][Full Text] [Related]
20. The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression.
Chesi M; Bergsagel PL; Kuehl WM
Curr Opin Hematol; 2002 Jul; 9(4):288-93. PubMed ID: 12042702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]